Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.
🇮🇳 India Edition • Healthcare, Pharma & Life SciencesRDU GLOBAL CORRESPONDENT
VERIFIED WIRE INTELLIGENCE
"Motilal Oswal Sees Aster DM EBITDA Rising 25% CAGR Through FY28, Sets Rs 910 Target"
Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.
Motilal Oswal Sees Aster DM EBITDA Rising 25% CAGR Through FY28, Sets Rs 910 Target
R
RDU Global Wire
Macro Economy & Fiscal Policy Desk
New Delhi, India Just now (12:26 PM IST)•5 min read
Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.
Editorial & Verification Notice
Reported by RDU Global Correspondent. Formatted and verified using real-time institutional and journalistic wire feeds. Independent reporting adhering to the RDU Global Editorial Code of Conduct.
Related Coverage
Healthcare, Pharma & Life Sciences
17 Oct 2026, 05:00 PM ISTHealth Tech Moves From Promise to Market Reality
A new wave of healthcare technology is moving from laboratory concept to commercial scale, with sensors, wearables, 3D-printed skin, reconstructed organs and AI-driven clinical trials reshaping how care is delivered and financed. For investors, the opportunity is broadening beyond medtech hardware into data platforms, personalized medicine and the infrastructure that supports faster, cheaper and more precise treatment.
Healthcare, Pharma & Life Sciences
16 Oct 2026, 01:35 PM ISTMHA to Seek Punjab’s Response After Recent Narcotics-Linked Deaths Raise Alarm
The Union Home Ministry is expected to seek a formal response from the Punjab government after a series of recent narcotics-related deaths intensified concern over the state’s drug crisis. Amit Shah said the drug trade is expanding, organised crime is deepening, and questions are being raised over the safety of those who speak against narcotics.
Healthcare, Pharma & Life Sciences
16 Oct 2026, 12:33 PM ISTAmit Shah Praises Assam’s Anti-Drug Drive, Signals Continued Federal Backing for Crackdown
Union Home and Cooperation Minister Amit Shah has praised the Assam Chief Minister and the Assam Police for their sustained action against narcotics trafficking and for delivering decisive blows to drug networks. The remarks underscore New Delhi’s continued emphasis on coordinated enforcement in India’s Northeast, a region long exposed to cross-border trafficking routes and organized criminal supply chains.